ACO/ARO/AIO-21 - Capecitabine-based chemoradiotherapy in combination with the IL-1 receptor antagonist anakinra for rectal cancer Patients: A phase I trial of the German rectal cancer study group

ACO/ARO/AIO-21 - Capecitabine-based chemoradiotherapy in combination with the IL-1 receptor antagonist anakinra for rectal cancer Patients: A phase I trial of the German rectal cancer study group

Purpose: Recent advances in the treatment algorithm of locally advanced rectal cancer (LARC) have significantly improved complete response (CR) rates and disease-free survival (DFS), but therapy resistance, with its substantial impact on outcomes and survival, remains a major challenge. Our group ha...

Full description

Bibliographic Details
Main Authors: Maximilian Fleischmann, Markus Diefenhardt, Adele M. Nicolas, Franz Rödel, Michael Ghadimi, Ralf-Dieter Hofheinz, Florian R. Greten, Claus Rödel, Emmanouil Fokas
Format: Article
Language:English
Published: Elsevier 2022-05-01
Series:Clinical and Translational Radiation Oncology
Subjects:
Rectal cancer
Anakinra
phase I
Chemoradiotherapy
Fibroblast
Interleukin-1
Online Access:http://www.sciencedirect.com/science/article/pii/S240563082200026X

Internet

http://www.sciencedirect.com/science/article/pii/S240563082200026X

Similar Items